A new, easily ingested form of a compound that has already shown it can attack the roots of leukemia in laboratory studies is moving into human clinical trials, according to a new article by University of Rochester investigators in the journal, Blood.
One of the biggest problems in the current treatment of cancer is that the agents that are efficacious in the destruction of tumorous cells are, at the same time, extremely toxic for the rest of the healthy cells and tissues of the patient. To address the problem the University of the Basque Country (UPV/EHU) is seeking more specific treatments and studying the differences between tumorous cells and healthy ones.
Phylonix Pharmaceuticals, Inc. today announced that it has been awarded a $1,092,031 Phase II Small Business Innovation Grant (SBIR) from the National Eye Institute of the National Institutes of Health (NIH) to develop zebrafish eye disease models for drug screening. The grant for “New Models for Eye Diseases” will support the Phylonix program over a period of three years.
A cadre of private and public entities in the addiction treatment field announced the launch of the National Adopting Changes to Improve Outcomes Now (ACTION) Campaign for the improvement of addiction treatment services. The ACTION Campaign goals are to increase access to addiction treatment for individuals in need and to keep clients engaged in treatment.
The American College of Physicians and the American Pain Society today released joint guidelines on diagnosing and treating low back pain.
Youth who have been homeless for any period of time after leaving the foster care system appear to have more problems accessing health care than those with stable housing situations, according to a report in the October issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
A combined treatment with rapamycin and Gleevec might reverse the effects of portal hypertension in patients with chronic liver disease, according to the results of a new study on rats.
University of Manchester researchers will reveal new ways of controlling and treating breast cancer at the National Cancer Research Institute conference in Birmingham today Monday, Oct. 1, 2007.
The new study reveals that, in rats, chronic nicotine use recruits a major brain stress system, the extrahypothalamic corticotropin releasing factor (CRF) system, which contributes to continued tobacco use by exacerbating anxiety and craving upon withdrawal. The researchers found that administering a compound that blocked the receptors involved in this stress system alleviated withdrawal symptoms.
Amylin Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the SymlinPen(TM) 120 and the SymlinPen(TM) 60 pen-injector devices for administering SYMLIN(R) (pramlintide acetate) injection.